Percutaneous left atrial appendage occlusion: New perspectives for the method

Gorczyca, Iwona; Wożakowska−Kapłon, Beata

doi:10.5603/cj.a2017.0029

Cited by 3 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After LAAC, the risk of thrombosis on the surface of the implanted device is high, and thus, anticoagulant or antiplatelet therapy is required until the epithelialization is finally achieved. Such postoperative therapy can decrease the incidence of adverse events in patients (16). However, the optimal type of treatment and the optimal duration of therapy remains unclear.…”

Section: Multivariate Logistic Regression Analysis Of Factors Influen...mentioning

confidence: 99%

Safety and efficacy of different anticoagulation regimens after left atrial appendage occlusion

Li¹,

Gao²,

Zhao³

et al. 2022

Ann Palliat Med

View full text Add to dashboard Cite

Background: This study examined the safety and efficacy of different anticoagulation regimens in patients with atrial fibrillation (AF) after left atrial appendage occlusion (LAAC) using the Watchman closure device. Methods: AF patients who underwent LAAC using the Watchman closure device in the Department of Cardiology, Jiangsu Taizhou People's Hospital between March 2018 and November 2019 were retrospectively enrolled in this study. Patients were divided into two groups according to different postoperative anticoagulant regimens. One group was treated with anticoagulant therapy alone [oral anticoagulant (OAC)/new OAC (NOAC) group] and the other was given NOACs combined with single antiplatelet therapy (SPAT) (NOAC + SAPT group). The incidences of ischemic stroke/transient ischemic attack (TIA), major bleeding events, all-cause mortality, and device-related thrombosis (DRT) were recorded. Furthermore, multivariate regression was used to analyze the factors associated with the occurrence of early DRT.Results: A total of 160 patients, including 42 (51%) females, with a mean age of 69.13±6.14 years were enrolled in this study. The mean CHA 2 DS 2 -VASc score was 3.66±1.11 and the mean HAS-BLED score was 4.16±0.82. During the postoperative follow-up period, there were no significant differences in the incidence of ischemic stroke/TIA [hazard ratio (HR) =0.616; 95% confidence interval (CI): 0.056 to 6.818; P=0.693], major bleeding events (HR =0.520; 95% CI: 0.047 to 5.764; P=0.594) nor all-cause mortality (HR =0.579; 95% CI: 0.052 to 6.394; P=0.656) between the two groups. However, the incidence of early DRT was higher in the OAC/NOAC group compared to the NOAC + SAPT group [odds ratio (OR) =0.120; 95% CI: 0.015 to 0.984; P=0.048]. Multivariate regression confirmed that atrial blood stasis (OR =11.367; 95% CI: 1.394 to 92.687; P=0.023) and peri-device leak (OR =9.337; 95% CI: 1.623 to 53.727; P=0.012) were independent predictors of early DRT.Conclusions: Short-term NOAC + SAPT after LAAC did not significantly increase the incidence of major bleeding events, ischemic stroke/TIA, nor all-cause mortality compared to OAC/NOAC therapy. Not only was NOAC + SAPT therapy found to be safe and effective in short-term follow-up, but it also lowered the risk of early DRT.

show abstract

Section: Multivariate Logistic Regression Analysis Of Factors Influen...mentioning

confidence: 99%

Safety and efficacy of different anticoagulation regimens after left atrial appendage occlusion

Li¹,

Gao²,

Zhao³

et al. 2022

Ann Palliat Med

View full text Add to dashboard Cite

show abstract

“…On the other hand, in cases with severe/ /life-threatening bleedings with no clear secondary/reversible/treatable cause the potential risks of re-initiating anticoagulation may outweigh the benefits of NOAC therapy [1]. In such situations, percutaneous or surgical left atrial appendage occlusion may be considered as a valuable option instead of long-term anticoagulation [1,4,100]. Finally, whether the use of PCC or aPCC is useful in NOAC-related intracranial bleeding is still hotly debated [101][102][103][104] since a multicentre analysis did not reveal a significant benefit on hematoma enlargement [105].…”

Section: Life-threatening Bleedingsmentioning

confidence: 99%

Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation — Messages from the 2018 EHRA

et al. 2018

View full text Add to dashboard Cite

show abstract

Long-term outcomes of left atrial appendage occlusion in patients with atrial fibrillation and end stage renal disease

Chang

Tsai

Lin

et al. 2024

Journal of the Formosan Medical Association

View full text Add to dashboard Cite

Percutaneous left atrial appendage occlusion: New perspectives for the method

Abstract: Ischemic stroke is a common complication of atrial fibrillation (AF). (Cardiol J 2017; 24, 5: 554-562)

Cited by 3 publications

References 36 publications

Safety and efficacy of different anticoagulation regimens after left atrial appendage occlusion

Safety and efficacy of different anticoagulation regimens after left atrial appendage occlusion

Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation — Messages from the 2018 EHRA

Long-term outcomes of left atrial appendage occlusion in patients with atrial fibrillation and end stage renal disease

Contact Info

Product

Resources

About